Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Non-Current Assets: 2022-2025

Historic Non-Current Assets for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Sep 2025 value amounting to $1.0 million.

  • Corvus Pharmaceuticals' Non-Current Assets fell 25.11% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year decrease of 25.11%. This contributed to the annual value of $1.3 million for FY2024, which is 7.78% down from last year.
  • According to the latest figures from Q3 2025, Corvus Pharmaceuticals' Non-Current Assets is $1.0 million, which was down 9.30% from $1.1 million recorded in Q2 2025.
  • Over the past 5 years, Corvus Pharmaceuticals' Non-Current Assets peaked at $1.8 million during Q1 2022, and registered a low of $1.0 million during Q3 2025.
  • Its 3-year average for Non-Current Assets is $1.3 million, with a median of $1.3 million in 2024.
  • In the last 5 years, Corvus Pharmaceuticals' Non-Current Assets grew by 0.98% in 2024 and then fell by 25.11% in 2025.
  • Quarterly analysis of 4 years shows Corvus Pharmaceuticals' Non-Current Assets stood at $1.7 million in 2022, then fell by 13.62% to $1.4 million in 2023, then declined by 7.78% to $1.3 million in 2024, then decreased by 25.11% to $1.0 million in 2025.
  • Its Non-Current Assets stands at $1.0 million for Q3 2025, versus $1.1 million for Q2 2025 and $1.2 million for Q1 2025.